Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing key technologies in the fields of genetic engineering and personalized medicine. Founded in 2016, Canopy has offices and laboratories in St. Louis, MO.
Location: United States, Missouri
Employees: 51-200
Phone: +1 314-833-9764
Total raised: $2.4M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Missouri T... | missourite... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.05.2018 | Series A | $2.4M | - |
Mentions in press and media 5
| Date | Title | Description |
| 07.12.2021 | Bruker : Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry | Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry Ready-to-Use Reagents to Advance Spatial Biology Research Fluorescent image of human lung cancer FFPE sample with 13 protein biomarkers illuminated u... |
| 30.04.2019 | Canopy Biosciences Acquires Zellkraftwerk | Canopy Biosciences, a St. Louis, MO-based provider of gene editing and gene expression products and services, acquired Zellkraftwerk GmbH, a Leipzig, Germany-based multiplex cytometry company. Concurrent with the acquisition, Canopy closed ... |
| 23.05.2018 | Term Sheet — Wednesday, May 23 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop “When I looked around, I saw a lot of women who were starting businesses,” she told Term Sheet. “I recognized that in the... |
| 22.05.2018 | Gene editing startup Canopy Biosciences raises $2.4 million in Series A financing to advance the development of research tools | Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targ... |
| 22.05.2018 | Canopy Biosciences Closes $2.4M Series A Funding | Canopy Biosciences, a St. Louis-based life sciences company, closed a $2.4m Series A financing. BioGenerator, the investment arm of BioSTL, and Kingdom Capital co-led the round, which saw participation from The Missouri Technology Corporati... |